S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
CEO of America's biggest bank has stern warning (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
AI Stock Caught Trading Under Secret Name (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
AI Stock Caught Trading Under Secret Name (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
CEO of America's biggest bank has stern warning (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
AI Stock Caught Trading Under Secret Name (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
AI Stock Caught Trading Under Secret Name (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
CEO of America's biggest bank has stern warning (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
AI Stock Caught Trading Under Secret Name (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
AI Stock Caught Trading Under Secret Name (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
CEO of America's biggest bank has stern warning (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
AI Stock Caught Trading Under Secret Name (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
AI Stock Caught Trading Under Secret Name (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
NASDAQ:DRMAW

Dermata Therapeutics (DRMAW) Stock Price, News & Analysis

$0.01
0.00 (0.00%)
(As of 02/23/2024 ET)
Today's Range
$0.0140
$0.0140
50-Day Range
$0.01
$0.03
52-Week Range
$0.01
$0.07
Volume
N/A
Average Volume
8,691 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Dermata Therapeutics

Dermata Therapeutics, Inc., a clinical-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

DRMAW Stock Price History

DRMAW Stock News Headlines

See More Headlines
Receive DRMAW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:DRMAW
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Gerald T. Proehl (Age 65)
    Founder, President, CEO & Chairman
    Comp: $352.92k
  • Mr. David F. Hale (Age 75)
    Co-Founder & Lead Independent Director
    Comp: $18.12k
  • Ms. Kyri K. Van Hoose CPA (Age 45)
    M.B.A., Senior VP & CFO
    Comp: $328.75k
  • Dr. Christopher J. Nardo M.P.H. (Age 59)
    Ph.D., Senior VP & Chief Development Officer
    Comp: $329.92k
  • Mr. Sean Proehl
    Senior Director of Legal & Business Development
  • Dr. Maria Bedoya Toro Munera M.B.A. (Age 72)
    Ph.D., Senior Vice President of Regulatory Affairs & Quality Assurance
    Comp: $27.04k














DRMAW Stock Analysis - Frequently Asked Questions

How have DRMAW shares performed in 2024?

Dermata Therapeutics' stock was trading at $0.0070 on January 1st, 2024. Since then, DRMAW shares have increased by 100.0% and is now trading at $0.0140.
View the best growth stocks for 2024 here
.

Are investors shorting Dermata Therapeutics?

Dermata Therapeutics saw a drop in short interest in the month of January. As of January 31st, there was short interest totaling 9,800 shares, a drop of 26.3% from the January 15th total of 13,300 shares. Based on an average daily volume of 4,800 shares, the days-to-cover ratio is currently 2.0 days.
View Dermata Therapeutics' Short Interest
.

How do I buy shares of Dermata Therapeutics?

Shares of DRMAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DRMAW) was last updated on 2/24/2024 by MarketBeat.com Staff